Stephen MacMillan

Stephen MacMillan has served as Chairman, President, and CEO of Hologic since 2013, focusing the company squarely on women's health and building it into the dominant player in breast cancer screening, cervical cancer screening, and women's health diagnostics. MacMillan's strategic clarity — concentrating on women's health rather than diversifying — has been the key to Hologic's success. Hologic's mammography business is the crown jewel: the Genius 3D Mammography (tomosynthesis) system has captured over 70% of the U.S. digital mammography installed base, demonstrating clinically superior cancer detection rates compared to traditional 2D mammography. The recurring revenue from mammography service contracts and consumables provides a stable base. In cervical cancer screening, Hologic's ThinPrep Pap test and Aptima HPV assay are market leaders. The molecular diagnostics division operates the Panther automated testing platform, which processes assays for sexually transmitted infections (chlamydia, gonorrhea, HPV, trichomonas) and expanded into COVID-19 testing during the pandemic. The surgical division provides minimally invasive solutions for gynecological conditions. Key stock drivers include mammography system placement trends, Genius AI adoption, molecular diagnostics test volumes, post-pandemic COVID testing normalization, surgical procedure volumes, and competition from GE HealthCare and Siemens Healthineers in imaging.